


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|------------------------------|
| USAN | TRELAGLIPTIN |
| PRONUNCIATION | trel" a glip' tin |
| THERAPEUTIC CLAIM | Treatment of type 2 diabetes |

CHEMICAL NAMES

1. Benzonitrile, 2-[[6-[(3*R*)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2*H*)-pyrimidinyl]methyl]-4-fluoro-
2. 2-({6-[(3*R*)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}methyl)-4-fluorobenzonitrile

STRUCTURAL FORMULA



| | |
|----------------------------|--|
| MOLECULAR FORMULA | C ₁₈ H ₂₀ FN ₅ O ₂ |
| MOLECULAR WEIGHT | 357.4 |
| TRADEMARK | None as yet |
| SPONSOR | Takeda Pharmaceutical Company Limited |
| CODE DESIGNATION | SYR-472 |
| <u>CAS</u> REGISTRY NUMBER | 865759-25-7 |